|
 News
Customer
Stories
About
Us
Contacts
|
 Abbott to Acquire STARLIMS Technologies
Ltd., a Leader in Laboratory Information
Management Systems
Enhances Abbott's Diagnostics Portfolio and Expertise in Information Management Systems; Expands STARLIMS' Presence Across Laboratory Market Segments
December 14, 2009 -- Abbott Park, Illinois and Hollywood Florida — Abbott (NYSE: ABT) announced today a definitive agreement to acquire STARLIMS Technologies Ltd. (NASDAQ: LIMS), a leading provider of laboratory information management systems, for approximately $123 million in cash.
The acquisition strengthens Abbott's competitive position in the global diagnostics market, providing advanced web-based applications to help laboratories efficiently store, retrieve and analyze a significantly increasing volume of clinical, managerial and administrative data.
"The acquisition of STARLIMS will provide Abbott with leading products to build upon existing technologies and expertise in the emerging field of healthcare informatics," said Edward L. Michael, executive vice president, Diagnostics Products, Abbott. "STARLIMS' advanced web-based technologies can help our customers operate efficiently across the core laboratory, molecular and point-of care segments of the global diagnostics market."
Healthcare informatics is the application of information management and technology to the planning and delivery of high quality and cost-effective healthcare. Advanced informatics systems are becoming increasingly important to clinical laboratories as a means to automate the retrieval, communication and management of medical and laboratory data and aid compliance with global regulatory and industry standards. Informatics systems can help laboratories improve operating efficiency through process standardization, reduced labor costs and increased capacity. Improved laboratory operations benefit physicians and patients through improved turnaround times and more consistent interpretation of test results.
As Abbott integrates STARLIMS into its existing portfolio of laboratory information management products, the company will continue to support and expand the non-clinical market segments currently served by STARLIMS.
"We believe our laboratory information management solutions, which are widely used by government, manufacturing and life sciences organizations, have important applications in clinical laboratories for improving the access, exchange and analysis of patient and technical data," said Itschak Friedman, chief executive officer of STARLIMS, who will continue to lead the STARLIMS team after the acquisition closes. "We look forward to becoming a part of Abbott and working together to serve our current customers and expand the availability of our technologies to address unmet needs in laboratories around the world."
Under the terms of the agreement, Abbott will acquire all outstanding equity of STARLIMS for $14 per share, for a total purchase price of approximately $123 million. STARLIMS currently has approximately $18 million in cash on hand.
This transaction does not impact Abbott's previously issued ongoing earnings-per-share guidance for 2009 and is subject to customary closing conditions. Abbott expects the transaction to close in the first quarter of 2010.
 About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
About STARLIMS
STARLIMS Technologies Ltd. (Nasdaq:LIMS) is a leading provider of laboratory information management systems (LIMS), with over 20 years of LIMS experience. The Company's flagship product, STARLIMS®, improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities. STARLIMS software is used for quality assurance and control, testing and monitoring, and research and development in government, manufacturing and life sciences organizations. With operations in the United States, Canada, the United Kingdom, Israel and Hong Kong, the company serves over 500 organizations in 40 countries. For more information, please see http://www.starlims.com.
###
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, changes in general economic and business conditions, changes in demand for products and services, the timing and amount or cancellation of orders, loss of market share and other risks detailed from time to time in STARLIMS's filings from time to time with the Securities and Exchange Commission. Such filings contain and identify these and other important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. Shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update publicly or revise any forward-looking statement.
Contacts:
Media:
Don Braakman
(847) 937-0080
Financial:
Tina Ventura
(847) 935-9390
STARLIMS contact:
Staci Mortenson
(203) 682-8273
### |
|
